News ( Year: 2019 )

SORT BY YEAR
16 December, 2019

Ally Bridge Group Leads More Than US$140 million in Financings for Three New Medtech Investments, Bringing Total Ally Bridge-led Private Life Science Investments to Above US$500 million over the Last 18 Months

HONG KONG and NEW YORK, Dec. 16, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, has announced that it recently led investments in three new medical technology companies. Each of the three companies is a commercial-stage, leading innovator re-setting the standard of care in its respective category. They include: Imperative Care (Campbell, CA) — A […]

Read More
11 December, 2019

Ally Bridge Group Co-leads Imperative Care’s $85 Million Series C Financing

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in neurovascular devices treating ischemic and hemorrhagic strokes. The round was co-led by new investors Ally Bridge […]

Read More
4 December, 2019

Ally Bridge Group Leads Venclose’s $27 Million Series C Funding

SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C funding led by Ally Bridge Group (ABG). ABG is a global life science-focused group with a successful investment record globally in supporting high-growth innovative life […]

Read More
10 May, 2019

Ally Bridge Portfolio News – Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick Sung, Ph.D. as its Chief Financial Officer. The financing was led by Ally Bridge Group, a leading global life science-dedicated investment group, and included other […]

Read More
10 May, 2019

Ally Bridge Group Leads Pulmonx’s $65 Million Financing, Further Strengthening Its Global Medtech Franchise

HONG KONG, May 9, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, announced today that it led an over-subscribed $65 million financing of Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies with its key product approved and marketed in the US, Europe, Australia, and Asia, including China. Pulmonx is focused on developing life-changing technologies […]

Read More
4 April, 2019

Ally Bridge, LifeTech Scientific and Quantum Surgical Announce Three-Way China Joint Venture to Develop Innovative Surgical Robot for the Treatment of Liver Cancer

HONG KONG, SHENZHEN, China, and Montpellier, France, April 4, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, announced today that it has entered into an agreement with LifeTech Scientific Corporation (SEHK: 1302) (“LifeTech”), a leading medical device company in China, and Quantum Surgical, an innovative surgical robotics company in […]

Read More
8 March, 2019

Ally Bridge Portfolio News – ShockWave Medical shares soared by more than 79% in its Wall Street debut

ShockWave Medical Inc. shares soared by more than 79 percent in its Wall Street debut on Thursday after it raised nearly $97 million in an upsized IPO. The Santa Clara life sciences company sold 5.7 million shares of common stock for $17 a share. That was about 700,000 more shares than were expected to be […]

Read More
8 March, 2019

Ally Bridge Portfolio News – ShockWave Medical prices upsized IPO above the range at $17

SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) — ShockWave Medical, Inc. (“ShockWave”) today announced the pricing of its initial public offering of 5,700,000 shares of its common stock at a price to the public of $17.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on March 7, […]

Read More